Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of QCZ484 in mild to moderate hypertension
jRCT2031250149Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of QCZ484 in hypertension (HTN) (6 arms), sponsored by Novartis. Primary endpoint: Change from baseline at Month 3 in mean 24-hour systolic blood pressure. Started Jun 2025; status: active, not recruiting.
02
Drugs
QCZ484
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2031250149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250149.